同种异体造血干细胞移植中移植物抗宿主病的临床应用中调节性 T 细胞的体外扩增。
Ex vivo expansion of regulatory T cells for clinical applications against graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
机构信息
Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
出版信息
Chin Med J (Engl). 2013 Dec;126(23):4575-82.
OBJECTIVE
To review the characteristics of regulatory T cells (Tregs) and ex vivo expansion of Tregs for treatment of graft-versus-host disease (GVHD).
DATA SOURCES
The data used in this review were retrieved from PubMed (1970-2013). The terms "ex vivo expansion", "regulatory T cell", and "graft-versus-host disease" were used for literature search.
STUDY SELECTION
The publications about the characteristics of Tregs, ex vivo expansion of Tregs and clinical applications of Tregs against GVHD were identified, retrieved and reviewed.
RESULTS
Tregs can be classified as natural Tregs (nTregs) and induced Tregs (iTregs). Both subsets share most Treg features. Given their immunosuppressive property, Tregs have been tested for their capability of preventing GVHD. The bottleneck of Treg therapy is the limited numbers of naturally existing Tregs. To solve this problem, ex vivo expansion of nTregs or iTregs has been executed. The initial data indicate Treg therapy is effective in reducing GVHD without compromising graft-versus-leukemia (GVL).
CONCLUSION
Ex vivo expansion of Tregs is a reliable way to prepare sufficient number of Tregs for management of GVHD.
目的
综述调节性 T 细胞（Tregs）的特性及其体外扩增用于移植物抗宿主病（GVHD）治疗的研究进展。
资料来源
检索 PubMed 数据库（1970 年至 2013 年），检索词为“ex vivo expansion”“regulatory T cell”和“graft-versus-host disease”，纳入关于 Tregs 特性、体外扩增及其在 GVHD 治疗中应用的文献。
选择标准
选择关于 Tregs 特性、体外扩增及其在 GVHD 治疗中应用的文献，进行筛选和综述。
结果
Tregs 可分为天然 Tregs（nTregs）和诱导 Tregs（iTregs），这两个亚群具有大多数 Treg 特征。鉴于其免疫抑制特性，人们已经研究了 Tregs 预防 GVHD 的能力。Treg 治疗的瓶颈在于天然存在的 Tregs 数量有限。为了解决这个问题，已经进行了 nTregs 或 iTregs 的体外扩增。初步数据表明，Treg 治疗可有效减轻 GVHD，而不影响移植物抗白血病（GVL）。
结论
Tregs 的体外扩增是为 GVHD 管理准备足够数量 Tregs 的可靠方法。
Zotero 插件